Document is current

Article History

Received: 11 May 2023

Accepted: 14 August 2023

First Online: 26 August 2023

Declarations

:

: The experiment on xenograft models and the animal facility followed the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines and were approved according to the institutional guidelines and the German animal welfare regulations (approval agency DD24-5131/207/34). Data from the retrospective cohort of the DKTK-ROG that received primary RCTx were first published in Linge et al. []. For this patient cohort, ethical approval of clinical and biological data was obtained from the Ethics Committees of all DKTK partner sites.

: Not applicable.

: Michael Baumann, CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg) is responsible for collaborations with a large number of companies and institutions worldwide. In this capacity, he has signed contracts for research funding and/or collaborations, including commercial transfers, with industry and academia on behalf of his institute(s) and staff. He is a member of several supervisory boards, advisory boards and boards of trustees. Michael Baumann confirms that he has no conflict of interest with respect to this paper. In the past 5 years, Mechthild Krause received funding for her research projects by Merck KGaA (2018–2020 for clinical study) and a publicly funded project with the companies Medipan, Attomol GmbH, GA Generic Assays GmbH, Gesellschaft für medizinische und wissenschaftliche genetische Analysen, Lipotype GmbH, and PolyAn GmbH (2019–2022). For the present study, Mechthild Krause confirms that none of the above mentioned funding sources were involved.